Magellan Rx, the pharmacy benefit management (PBM) division that became part of Prime Therapeutics in December 2022, administers pharmacy claims and performs PBM audits for commercial health plans and, in several states, Medicaid managed care organizations. A pharmacy that receives a Magellan Rx audit notice faces the scrutiny typical of any PBM review. When the underlying claims were billed to a state Medicaid managed care plan, an adverse finding can create exposure on two tracks at once: the PBM's own contractual recoupment process, and a possible referral to the state Medicaid program integrity unit. The stakes, including network termination, make an early response important.
Background
Magellan Rx Management has long held contracts with a number of state Medicaid programs. Prime completed its $1.35 billion acquisition of Magellan Rx from Centene Corporation on December 5, 2022, combining Magellan Rx's specialty and government-program pharmacy business with Prime's existing PBM operations. Magellan Rx, operating in some state contracts as Magellan Medicaid Administration, serves as the pharmacy benefit administrator for multiple state Medicaid programs and managed care plans. In Louisiana, for example, Magellan Medicaid Administration became the single pharmacy benefit manager for every Medicaid managed care organization in the state, a role that includes pharmacy network management and auditing.
How Magellan Rx Pharmacy Audits Work
Like other PBMs, Magellan Rx reviews pharmacy claims through desk audits, conducted by mail or electronically from submitted records, and on-site audits, in which an auditor reviews hard-copy prescriptions, inventory, and signature logs on site. Audit selection is typically driven by claims analytics, including unusual reimbursement patterns, high-cost or compounded prescriptions, and prescriber or drug combinations that deviate from peer norms. An audit notice generally sets a deadline to produce prescription records, invoices, and delivery documentation. A step-by-step walkthrough is available in Health Law Alliance's guide on how to respond to a PBM audit letter.
Findings can lead to a demand for recoupment of amounts already paid and, in more serious cases, a network termination action. Pharmacies generally have the right to pursue an audit appeal through Magellan Rx's internal process before recoupment is finalized. The mechanics resemble those used by other PBMs, including Humana and MedImpact, though each maintains its own timelines and documentation standards.
Dual-Track Exposure in Managed Medicaid Audits
The overlap between Magellan Rx's commercial PBM role and its Medicaid managed care contracts creates the dual-track exposure that sets these audits apart from a typical commercial review. Federal regulations require state Medicaid managed care plans, known as MCOs, to build fraud, waste, and abuse detection into contracts with subcontractors such as PBMs, and to promptly refer potential fraud, waste, or abuse to the state Medicaid program integrity unit, with potential fraud referred directly to the state Medicaid Fraud Control Unit (42 C.F.R. § 438.608(a)(1), (a)(7)).
A Magellan Rx audit tied to Medicaid managed care claims can proceed on two tracks at once: the PBM's own contractual recoupment process, and a separate referral to the state Medicaid program integrity unit.
In practice, a Magellan Rx finding tied to Medicaid managed care claims does not automatically stay inside the PBM's audit and recoupment process. If an auditor treats a documentation defect as a knowing or repeated billing pattern instead of a single clerical error, the same claims can become the basis for a separate state program integrity inquiry, with exposure under the state's false claims statute layered on the PBM's recoupment demand. Because Magellan Rx administers both commercial and Medicaid managed care claims, pharmacies under audit should confirm early which type of claims are driving the review.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a Magellan Rx audit notice, subpoena, or other government inquiry tied to Medicaid managed care claims. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to audit and investigative requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with the PBM and any government investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk, particularly where the same claims may be reviewed by both the PBM and a state program integrity unit.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies nationwide in PBM audits and in related state Medicaid program integrity matters, drawing on the firm's experience with 2,000+ audits overseen on behalf of pharmacy clients. The firm's attorneys work with pharmacies facing Magellan Rx audits through the documentation request, the audit response, and any appeal, and coordinate a defense when a Medicaid managed care audit carries a risk of referral to state program integrity or fraud units. Pharmacies that have received a Magellan Rx audit notice may contact Health Law Alliance's PBM audit defense team for a free, confidential consultation.
